AtaiBeckley (ATAI) shares were in focus after first quarter results showed a net loss of US$29.78 million and an earnings per share loss of US$0.08, with management highlighting cash resources and progress across key mental health programs.

The latest Q1 update, including the earnings beat and progress toward Phase 3 trials, comes against a backdrop of a 11.63% year to date share price return and a 109.71% 1 year total shareholder return. This suggests momentum has picked up after recent shorter term share price softness.

If this kind of move in a clinical stage pipeline has caught your attention, it can be worth scanning for other healthcare AI opportunities through our curated list of 34 healthcare AI stocks

With Q1 results beating expectations, a clinical pipeline moving toward late stage trials, and a share price still far below the consensus US$14 target, investors may be asking whether AtaiBeckley is offering mispriced upside or whether markets are already banking on future growth.

Preferred Price to Book of 8x: Is It Justified?

AtaiBeckley last closed at $4.32, and on a P/B of 8x the stock sits well above the broader US pharmaceuticals sector, where the average P/B is 2.3x.

The P/B ratio compares the company’s market value to its book value, which is essentially net assets on the balance sheet. For a clinical stage biopharma company with limited current revenue and ongoing losses, a higher P/B often reflects how much investors are willing to pay today for pipeline potential and future cash flows rather than existing earnings power.

In AtaiBeckley’s case, that 8x P/B suggests the market is assigning a sizeable premium to its mental health pipeline and expected revenue growth, even though the company is currently unprofitable and forecast to remain so over the next three years. The premium is meaningfully higher than the sector average, yet it is still well below the 16.9x peer average indicated in the data. This points to investors paying a lower multiple than some closer comparators for similar balance sheet value.

Against the wider US pharmaceuticals industry, AtaiBeckley’s 8x P/B is more than 3x the sector average of 2.3x. This underscores how differently the market is treating this stock relative to the broader group. Compared with the 16.9x peer average, the current multiple also sits at less than half that level, which could imply room for the valuation to shift if sentiment aligns more closely with peers or if expectations on the pipeline change.

Result: Price-to-Book of 8x (OVERVALUED)

However, the story can change quickly if key clinical trials disappoint or if ongoing net losses of US$663.40 million strain AtaiBeckley’s US$1.59b market cap valuation.

Another Way to Look at Value

While the 8x P/B screen suggests ATAI trades at a premium to the broader US pharmaceuticals group, the SWS DCF model points in the other direction. With an estimated future cash flow value of $6.01 versus the current $4.32 share price, the model indicates ATAI is trading below that cash flow estimate.

This creates a clear tension. One approach flags ATAI as expensive, and another frames it as undervalued. For you as an investor, the real question is which set of assumptions feels more realistic for a clinical stage pipeline stock like this.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out AtaiBeckley for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 48 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With sentiment clearly mixed around ATAI, it makes sense to look beyond headlines, review the full picture of risks and rewards, and decide quickly where you stand based on the 2 key rewards and 3 important warning signs in the 2 key rewards and 3 important warning signs.

Looking for more investment ideas?

If ATAI has sharpened your focus on opportunities, do not stop here. Broaden your watchlist and let data driven filters bring fresh stocks onto your radar.

• Target potential mispricings by scanning for companies flagged as 48 high quality undervalued stocks that combine quality fundamentals with discounted share prices.
• Prioritise resilience by reviewing 68 resilient stocks with low risk scores that score well on financial strength and business stability.
• Get ahead of the crowd by hunting through a screener containing 21 high quality undiscovered gems before they hit every investor’s radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.